Pasi Mäkelä - Chief Financial Officer, CFO | Strategic Finance & Process Development, Budgeting & Forecasting - Kiipulasäätiö | LinkedIn
![Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study - Reich - 2020 - British Journal of Dermatology - Wiley Online Library Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study - Reich - 2020 - British Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/de9e6553-4fc6-45fa-aa8d-f9728626ef2f/bjd18143-fig-0008-m.jpg)
Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study - Reich - 2020 - British Journal of Dermatology - Wiley Online Library
![Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial - The Lancet Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/4bac914f-0f1b-4ec4-b612-704d80ee7dd3/gr1_lrg.jpg)